The Lung Cancer Research Foundation (LCRF) is pleased to announce its partnership with Israel Cancer Research Fund (ICRF) on ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...
A discovery of how to target mutated proteins in tumors made a decade ago never matured into a surefire way of destroying ...
Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...
This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...
A new research paper was published in Oncotarget, Volume 16, on February 12, 2025, titled “Could Panitumumab with very low ...
Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...
Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...